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In order to identify targets whose inhibition may enhance the efficacy of chemoradiation in pancreatic cancer, we
previously conducted an RNAi library screen of 8,800 genes. We identified Mcl-1 (myeloid cell leukemia-1), an anti-
apoptotic member of the Bcl-2 family, as a target for sensitizing pancreatic cancer cells to chemoradiation. In the
present study we investigated Mcl-1 inhibition by either genetic or pharmacological approaches as a
radiosensitizing strategy in pancreatic cancer cells. Mcl-1 depletion by siRNA produced significant radio-
sensitization in BxPC-3 and Panc-1 cells in association with Caspase-3 activation and PARP cleavage, but only
minimal radiosensitization in MiaPaCa-2 cells. We next tested the ability of the recently identified, selective, small
molecule inhibitor of Mcl-1, UMI77, to radiosensitize in pancreatic cancer cells. UMI77 caused dissociation of Mcl-
1 from the pro-apoptotic protein Bak and produced significant radiosensitization in BxPC-3 and Panc-1 cells, but
minimal radiosensitization in MiaPaCa-2 cells. Radiosensitization by UMI77 was associated with Caspase-3
activation and PARP cleavage. Importantly, UMI77 did not radiosensitize normal small intestinal cells. In contrast,
ABT-737, an established inhibitor of Bcl-2, Bcl-XL, and Bcl-w, failed to radiosensitize pancreatic cancer cells
suggesting the unique importance of Mcl-1 relative to other Bcl-2 family members to radiation survival in
pancreatic cancer cells. Taken together, these results validate Mcl-1 as a target for radiosensitization of pancreatic
cancer cells and demonstrate the ability of small molecules which bind the canonical BH3 groove of Mcl-1,
causing displacement of Mcl-1 from Bak, to selectively radiosensitize pancreatic cancer cells.
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Pancreatic cancer is a highly aggressive disease that is associated with
both local and systemic disease progression. In the metastatic disease
setting, new chemotherapy regimens have produced modest survival
improvements [1,2] while in the locally advanced disease setting
antimetabolite-based chemoradiation has remained the standard of
care [3]. Although the combination of radiation with gemcitabine
improves survival over gemcitabine alone, recent clinical studies
suggest that intensification of radiation therapy in combination with
concurrent gemcitabine further improves survival [4]. Despite the
improvements afforded by concurrent gemcitabine and radiation
therapy, however, survival for locally advanced pancreatic cancer is
between 11 and 15 months [3,4].
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cancer we have previously investigated a number of strategies which
build upon standard gemcitabine-based chemoradiation therapy.
Incorporation of additional chemotherapeutic agents, such as
cisplatin and oxaliplatin, with gemcitabine-radiation does not appear
to improve survival but does increase toxicity [5,6]. Thus, targeted
therapies which are generally less toxic than standard chemotherapy
have been combined with gemcitabine-radiation. Preclinically, small
molecule inhibitors of Chk1 and Wee1 sensitize pancreatic tumors to
gemcitabine-radiation [7–9]. In order to identify additional targets for
sensitization of pancreatic cancers to gemcitabine-radiation using an
unbiased approach, we previously screened an RNAi library designed
to target 8,800 genes from the druggable genome [10]. In addition to
previously established targets for sensitization, such as Chk1 and
ATR, we identified Mcl-1 as a leading target for sensitization of
pancreatic cancer cells to gemcitabine-radiation.
Mcl-1 is an anti-apoptotic member of the Bcl-2 protein family that
negatively regulates the intrinsic apoptotic pathway [11]. By
sequestering the pro-apoptotic proteins Bax and Bak, Mcl-1 inhibits
permeabilization of the mitochondrial membrane, preventing
cyctochrome C release, Caspase-9 activation, and ultimately
apoptosis. Mcl-1 is subject to negative regulation by Noxa as well
as other members of the BH3-only protein family (e.g. Bim, Puma,
tBid), which specifically bind to the BH3 binding groove, formed by
BH1-3 domains of Mcl-1, displacing Mcl-1 from Bax/Bak and thus
promoting apoptosis. Overexpression of Mcl-1 has been shown to be
a mechanism of resistance to various cancer therapies including
radiation [12], chemotherapy [13–15], and agents targeting the Bcl-2
family of proteins [16,17]. In contrast, genetic silencing of Mcl-1
sensitizes a spectrum of cancers including melanoma, non-small cell
lung, and hepatocellular cancers to radiation [18], chemotherapy
[19,20], and Bcl-2 family inhibitors [21–23]. In pancreatic cancers,
Mcl-1 protein is expressed at high levels relative to normal pancreatic
tissue and is associated with advanced disease [24], and genetic
silencing of Mcl-1 sensitizes pancreatic cancers to either gemcitabine
or radiation [25,26].
Given the roles of Mcl-1 in promoting resistance to radiation,
chemotherapy, and Bcl-2 family inhibitors, the development of Mcl-1
selective inhibitors is an active area of investigation. While there are
several established small molecule inhibitors of other Bcl-2 family
members, such as ABT737 and its clinical derivative ABT263
(navitoclax), as well as ABT199 and GX15-070 (obotaclax) [27],
selective Mcl-1 inhibitors are in earlier stages of development. Selective
targeting of Mcl-1 has proven to be challenging relative to other Bcl-2
family members and may be attributable to the structure of Mcl-1 [28].
A few selective Mcl-1 inhibitors are in preclinical development [29],
such as the stapled peptide SAHB [30], the small molecules MIM1
[31], EU-5148 [19], and the compound 53 [32], as well as a novel class
of hydroxynapthalen aryl sulfonamides [33]. More recently, a small
molecule inhibitor of Mcl-1, designated UMI77, that engages Mcl-1 at
its canonical BH3-binding groove, was shown to have single agent
activity in human pancreatic cancer models both in vitro and
in vivo [34].
Based on our identification of Mcl-1 as a target for enhancing
chemoradiosensitization in pancreatic cancer, in this study we sought
to validate Mcl-1 as a target for radiosensitization and to investigate a
novel, pharmacologic approach for Mcl-1 inhibition. Following
confirmation of Mcl-1 as a radiosensitizing target in pancreatic cancer
cells using siRNA, we tested the ability of the small molecule inhibitorof Mcl-1, UMI77, to radiosensitize in pancreatic cancer cells and
normal small intestinal cells. To begin to understand the mechanisms
of radiosensitization by Mcl-1 inhibition, we investigated the ability
of UMI77 to prevent Mcl-1 and Bak complex formation and induce
apoptosis assessed by Caspase-3 activity and PARP-1 cleavage, as well
as sub-G1 DNA content.
Materials and Methods
Cell Culture, Drug Solutions, and RNAi
All cells were obtained from the American Type Culture
Collection. Cells were grown in DMEM (Panc-1, MiaPaCa-2),
RPMI1640 (BxPC-3) or HybriCare (ATCC) with 30ng/ml
epidermal growth factor (CCL-241, normal human small intestine
epithelial cells) media supplemented with and 10% fetal bovine
serum (Invitrogen), 2 mmol/L l-glutamine (Sigma) and penicillin/
streptomycin (Sigma). Experiments were conducted on exponentially
growing cells. Cells were tested for Mycoplasma once every 3 months.
UMI77 was dissolved in DMSO and stored at −20°C. Non-specific and
Mcl-1 siRNAs were purchased from Dharmacon and used as previously
described [10]. Cells were transfected with siRNA using Oligofectamine
(Invitrogen) or X-treme gene (Roche) transfection reagents.
Irradiation
Irradiations were performed using a Philips RT250 (Kimtron
Medical) at a dose rate of ∼2 Gy/min in the University of Michigan
Comprehensive Cancer Center Experimental Irradiation Core.
Dosimetry was carried out using an ionization chamber connected
to an electrometer system that is directly traceable to a National
Institute of Standards and Technology calibration.
Clonogenic Survival Assay
Clonogenic assays were carried out using standard techniques as
described previously [8,10]. For siRNA experiments, cells were
transfected at 30-50% confluency (as described above) and at 48
hours post-transfection plated at clonal densities and then irradiated.
For drug experiments, cells were plated at clonal densities and then
treated with UMI77 and radiation. Cells were grown at 37°C for 7–
12 days for colony formation. The cytotoxicity of UMI77 or Mcl-1
siRNA in the absence of radiation treatment was calculated as the
ratio of surviving treated cells relative to surviving vehicle or non-
specific siRNA -treated cells, respectively. Radiation survival data
from treated cells were corrected for plating efficiency by normalizing
to un-irradiated control cells. Cell survival curves were fitted using the
linear-quadratic equation, and the mean inactivation dose was
calculated and used to determine the radiation enhancement ratio
[35]. Radiosensitization is indicated by a radiation enhancement ratio
of significantly greater than 1.
Immunoblotting
Cells were washed with PBS (phosphate buffered saline) and lysed
in RIPA buffer (50mM Tris, pH 8.0, 150mM sodium chloride, 1.0%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease
and phosphotase inhibitor cocktails (Roche). Proteins were separated
by SDS-PAGE, transferred to nitrocellulose membranes (Invitrogen)
and probed with primary antibodies including those recognizing Mcl-
1 (S-19; Santa Cruz Biotechnology), PARP-1 (Cell Signaling), Bak
(Calbiochem) and β-actin (Abcam). HRP-conjugated secondary
antibodies (Santa Cruz) and chemiluminescence (ECL; Amersham
Biosciences) were used to detect specific protein signals.
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Figure 1.Mcl-1 depletion radiosensitizes pancreatic cancer cells. Panc-1 or BxPC-3 cells were treated with either non-specific (siNS)
or Mcl-1 siRNA (siMcl-1). Seventy-two hours post-transfection cells were treated with radiation (0-8Gy). Radiosensitization was assessed
by clonogenic survival and is indicated by an RER (radiation enhancement ratio) of greater than 1. Mcl-1 protein depletion by siRNA is
shown (inset). Data are from a single representative experiment (A, B) or are the mean ± standard error of 3 independent experiments (C).
Statistical significance versus siNS is indicated (*Pb0.05). Cytotoxicity is the surviving fraction of siMcl-1-treated cells relative to siNS, in
the absence of radiation.
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Exponentially growing pancreatic cancer cells were incubated with
UMI77 for 48 hours. Cell lysates were prepared with a solution of cold
NP-40 lysis buffer (50mM Tris, pH 7.4, 150mM NaCl, 1mM EDTA,
1mM DTT, 0.5% (v/v) NP-40, and Complete protease inhibitor
(Roche)). Cellular debris was pelleted at 14,000g for 15 min at 4°C, and
the supernatant was then collected and exposed to pre-equilibrated
protein A/G Sepharose beads (Santa Cruz Biotechnology). The pre-
cleared supernatant was incubated with either Mcl-1 antibody (S-19) or
an isotype control (Rabbit IgG; Santa Cruz Biotechnology), overnight at
4°C, followed by the addition of protein A/GSepharose beads for 2 hours.
The beads were pelleted and washed with cold NP-40 lysis buffer
followed by elution of the sample from the beads by heating at 95°C for
10 min in SDS loading buffer (60mM Tris pH 6.8, 2% SDS, 10%
glycerol, and 5% 2-mercaptoethanol). The immunoprecipitates were
subjected to electrophoresis and western analysis using an anti-BAK
antibody (CalBiochem).
Flow Cytometry
Cells were washed with PBS and resuspended in 70% ice-cold
ethanol. The cells were incubated overnight at 4°C and then washed
in PBS. The cells were then resuspended in prodium iodide (PI)
solution (50μg/ml PI, 200μg/ml DNase-free RNaseA in PBS) and
then analyzed by flow cytometry (FACSCanto, BD Biosciences). Cell
apoptosis after treatment was analyzed by measuring sub-G1 peaks
using FloJo software (TreeStar).
Caspase-3 Activity Assay
The immunoabsorbent Caspase-3 activity assay kit from Roche
was used to detect Caspase-3 activity after treatment with UMI77 orMcl-1 siRNA and radiation. Briefly, after treatment, lysates from 2 ×
107 cells were prepared and Caspase-3 was captured from the lysate in
microplates coated with anti-Caspase-3 monoclonal antibody. Plates
were washed, Ac-DEVD-AFC was added and the cleaved AFC was
determined using a spectrophotometer at 405nm. Samples were
calibrated to a standard curve generated from AFC stock solution.
Statistical Analysis
For radiosensitization experiments, statistical significance was
determined by a Student’s T-test using GraphPad Prism (GraphPad
Software Inc.).
Results
Given the identification of Mcl-1 in an RNAi library screen as a target
for sensitization of pancreatic cancer cells to chemoradiation (Suppl.
Fig. 1) [10], we initiated the present study by investigating the ability
of Mcl-1 depletion to radiosensitize pancreatic cancer cells. Mcl-1 was
depleted from BxPC-3 and Panc-1 cells via RNAi and radiation
sensitivity was determined with a clonogenic survival assay in both
cell lines. We found that treatment with Mcl-1 siRNA led to Mcl-1
protein depletion (Figure 1A, B, insets) and radiosensitization
(Figure 1) compared to treatment with non-specific siRNA. Radio-
sensitization by Mcl-1 depletion was evidenced by radiation
enhancement ratios between 1.3±0.04 and 1.5±0.06 in BxPC-3
and Panc-1 cells, respectively, (Figure 1C) which were significant in
comparison to their respective controls. In addition, we found that
MiaPaCa-2 cells were radiosensitized by Mcl-1 depletion (Suppl. Fig.
2A), although to a lesser extent than Panc-1 or BxPC-3 cells. Mcl-1
expression is relatively low in MiaPaCa-2 cells compared to Panc-1 or
BxPC-3 cells [34] and may account for the relative resistance of
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Figure 2. Mcl-1 depletion in combination with radiation causes Caspase-3 activation and PARP-1 cleavage. Panc-1 cells were
treated with siRNA and radiation (7.5Gy) as described in Figure 1. At 48 hours post-radiation, cells were prepared for Caspase-3 activity
assays (A, B) or immunoblotting (C, D). Data are the mean ± standard deviation of 2 independent experiments with each test performed in
duplicate (A, B) or are from a single representative experiment (C, D).
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target for radiosensitization in pancreatic cancer cells.
Based on the established functions of Mcl-1 in the intrinsic
apoptotic pathway, we hypothesized that Mcl-1 plays a critical role in
regulating apoptosis after radiation. In order to begin to determine
whether radiosensitization via Mcl-1 depletion is mediated by
induction of apoptosis, we assessed both Caspase-3 activity and
cleaved-PARP levels in BxPC-3 and Panc-1 cells following treatment
with Mcl-1 siRNA and radiation. In Panc-1 cells, we found that
depletion of Mcl-1 in the absence of radiation caused little to no
increase in Caspase-3 activity or PARP cleavage or (Figure 2A, C). In
combination with radiation however, Mcl-1 depletion led to both
increased Caspase-3 activity and increased PARP cleavage. Likewise,
depletion of Mcl-1 from BxPC-3 cells had no effect on either
Caspase-3 activity or cleaved PARP, while in combination with
radiation Mcl-1 depletion caused an increase in Caspase-3 activity
and PARP cleavage (Figure 2B, D). Taken together, these results
confirm that Mcl-1 is a target for sensitizing pancreatic cancer cells to
radiation, via induction of apoptosis.
In order to begin to develop a pharmacological strategy for
radiosensitization by Mcl-1 inhibition, we tested the ability of
UMI77, a recently characterized small molecule inhibitor of Mcl-1
[34], to radiosensitize pancreatic cancer cells. We began bydetermining the effects of minimally cytotoxic concentrations of
UMI77 on radiosensitization of Panc-1 and BxPC-3 cells according
to the schedule illustrated (Figure 3A). Treatment of Panc-1 cells with
UMI77 resulted in a concentration-dependent increase in radio-
sensitization evident by a decrease in survival in response to radiation
(Figure 3B) and statistically significant radiation enhancement ratios
of 1.3±0.08 to 1.5±0.07 (Figure 3D). BxPC-3 cells were also
significantly radiosensitized by UMI77 with a radiation enhancement
ratio of 1.3±0.04 (Figure 3C, D). Since high Mcl-1 expression levels
are associated with sensitivity to Mcl-1 inhibition, we also examined
the ability of UMI77 to radiosensitize MiaPaCa-2 cells which express
low levels of Mcl-1 relative to Panc-1 or BxPC-3 cells [34]. We found
that MiaPaCa-2 cells were less radiosensitized by UMI77 (radiation
enhancement ratio: 1.2; Suppl. Fig. 2B) than BxPC-3 or Panc-1 cells,
a finding which is consistent with the relatively low Mcl-1
expression [34] and minimal radiosensitization by Mcl-1 siRNA
(Suppl. Fig. 2A) in MiaPaCa-2 cells. Given the availability of other
Bcl-2 family inhibitors, we next sought to compare UMI77 to other
well-established Bcl-2 family inhibitors in the context of radio-
sensitization. In contrast to Mcl-1 inhibition by UMI77, we found
that ABT737, an inhibitor of Bcl-2, Bcl-XL, and Bcl-w, failed to
radiosensitize Panc-1 cells (Suppl. Fig. 3). This result is consistent
with the lack of identification of Bcl-2, Bcl-XL, or Bcl-w in our initial
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Figure 3. Inhibition of Mcl-1 by UMI77 radiosensitizes pancreatic cancer cells. Cells were treated with UMI77 (1-3μM) as illustrated
(A) and radiosensitization was assessed by clonogenic survival. Data are from a single representative experiment (B, C) or are the mean ±
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demonstrate that pharmacological inhibition of Mcl-1 is an effective
radiosensitizing strategy in pancreatic cancer cells and furthermore,
suggest that inhibition of Mcl-1 is uniquely effective relative to
inhibition of other Bcl-2 family members for radiosensitizing
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Bak interactions (Figure 4), a finding which is in agreement with the
concentration dependent radiosensitization observed in response to
UMI77 (Figure 3). Similarly, UMI77 inhibited Mcl-1-Bak interac-
tions in MiaPaCa-2 cells (Suppl. Fig. 2C). These data demonstrate
that UMI77 displaces Bak from Mcl-1 in pancreatic cancer cells and
suggest that dissociation of Bak from Mcl-1 is a mechanism of
radiosensitization by UMI77.
To further examine the mechanism of radiosensitization by
UMI77, we next assessed the ability of UMI77 to induce Caspase-
3 activation and PARP cleavage in response to radiation in pancreatic
cancer cells. In Panc-1 cells, treatment with either radiation or
UMI77 alone caused a concentration-dependent increase in Caspase-
3 activity and PARP cleavage (Figure 5A, C). In combination with
radiation, however, UMI77 caused a higher induction of Caspase-3
activity and PARP cleavage compared to treatment with either single
agent. Consistent with activation of the apoptotic pathways, UMI77
and radiation caused an increase in the number of cells with sub-G1
DNA content (Suppl. Fig. 4). Total Mcl-1 protein levels were
minimally affected under these treatment conditions, suggesting
UMI77 does not cause degradation of Mcl-1. Likewise, in BxPC-3
cells, UMI77 also caused Caspase-3 activation and PARP cleavageA
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radiation (Figure 5B, D). Taken together, these findings demonstrate
that the mechanism for radiosensitization of pancreatic cancer cells by
UMI77 involves displacement of Mcl-1 from the pro-apoptotic
protein Bak and subsequent induction of apoptosis.
To begin to determine whether radiosensitization by Mcl-1
inhibition is tumor cell selective, we assessed the ability of UMI77
to radiosensitize normal cells. Given that the dose limiting toxicity for
radiation treatment of pancreatic cancer is duodenum, normal human
small intestinal epithelial cells were chosen for this study. Treatment
of CCL-241 cells with UMI77 under identical conditions to those
used for pancreatic cancer cells did not result in significant
radiosensitization or cytotoxicity (Figure 6). These results suggest
that UMI77 confers selective radiosensitization of pancreatic cancer
cells while sparing normal intestine epithelial cells.
Discussion
Our initial identification of Mcl-1 as a sensitizing target in pancreatic
cancer among a library of 8,800 other potential targets suggests the
importance of Mcl-1 to the sensitivity of pancreatic cancers to
chemoradiation therapy. In this study we investigated the small
molecule Mcl-1 inhibitor, UMI77, as a novel radiosensitizer inB
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interactions, induces apoptosis in response to radiation, and
ultimately causes radiosensitization. Further supporting the exclusive
role of Mcl-1 in survival following radiation, we found that inhibition
of other anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-XL, and Bcl-
w) failed to radiosensitize pancreatic cancer cells. In addition, we
observed varying degrees of radiosensitization by Mcl-1 inhibition
across a panel of pancreatic cancer cells which may be reflective of
their varying Mcl-1 protein levels, with cells containing high levels of
Mcl-1 being the most sensitized by Mcl-1 inhibition [34].
Importantly, we found that UMI77 was selective for pancreatic
cancer cells as normal intestinal cells were not radiosensitized by
UMI77. The results of this study illustrate the unique importance of
Mcl-1 relative to other Bcl-2 family members for survival following
radiation and suggest that pancreatic cancer cells with high Mcl-1
expression may be selectively radiosensitized by Mcl-1 inhibition.
Since Mcl-1 has an established role in regulating apoptosis, we
investigated the effects of Mcl-1 siRNA or UMI77 on the apoptosis
pathway. Indeed, we found that either depletion or inhibition of Mcl-
1 in combination with radiation caused an increase in Caspase-3
activity and cleaved-PARP levels. These results suggest that apoptosis
is a mechanism of radiosensitization by Mcl-1 inhibition. Given that
Mcl-1 also has non-apoptotic functions such as regulation of the
DNA damage response [38,39], autophagy [40], mitochondrial
respiration [41], and cellular senescence [42], it is possible that one of
these mechanisms may contribute to radiosensitization as well. It is
not clear at this time whether small molecules such as UMI77 which
bind the canonical BH3 binding groove on Mcl-1, and block Mcl-1
interactions with pro-apoptotic proteins such as Bak and Bax, would
affect these non-apoptotic Mcl-1 functions.Mcl-1 is negatively regulated not only by BH3 proteins (e.g. Noxa,
Puma) which displace Mcl-1 from the pro-apoptotic proteins Bak and
Bax, but also by proteasomal degradation which has previously been
shown to be induced by Noxa [36,43]. Given that many of the Mcl-1
inhibitors currently under development are ‘Noxa-like’ (e.g. MIM1
and UMI77) and selectively displace Bak/Bax fromMcl-1 [27], it is of
interest to know whether these Noxa-like Mcl-1 inhibitors also
induce Mcl-1 degradation. Like Noxa, the putative Mcl-1 inhibitor
maritoclax was reported to induce Mcl-1 degradation [44]. However,
the bona fide BH3 mimetic, Mcl-1 inhibitor BIMS2A does not cause
Mcl-1 degradation [45]. Consistent with the lack of effect of BIMS2A
on Mcl-1 stability, we observed only minimal effects of UMI77 on
Mcl-1 protein levels (Figure 5C, D). While more detailed studies of
the effects of UMI77 on Mcl-1 degradation are required in the future,
these results suggest that the activity of UMI77 does not require Mcl-
1 degradation.
Although we did not investigate the activity of UMI77 in animal
tumor models, previous studies by Abulwerdi and colleagues [34]
have shown that UMI77 is well-tolerated and inhibits the growth of
pancreatic tumor xenografts with no apparent toxicity in normal
mouse tissues. Mechanistic studies revealed the presence of
TUNNEL-positive apoptotic cells in tumors collected from
UMI77-treated animals, further supporting our observations that
induction of apoptosis is a mechanism of action of UMI77. Since the
in vitro data in the present study demonstrated the efficacy of UMI77
as a radiosensitizing agent in pancreatic cancers, it will be important
in future studies to determine the anti-tumor effects as well as toxicity
of the combination of UMI77 with radiation in animal models.
Standard treatment for locally advanced pancreatic cancer is
concurrent antimetabolite-based chemoradiation. In particular, the
combination of gemcitabine with radiation is superior to gemcitabine
alone [3,4]. Thus, in the development of targeted agents for the
treatment of pancreatic cancer, interactions with gemcitabine are an
important consideration. Given that our initial RNAi screen
identified Mcl-1 as a target for sensitization to gemcitabine-radiation,
it is likely that small molecule Mcl-1 inhibitors will also sensitize to
gemcitabine-radiation. Determining the efficacy, toxicity, and
optimal schedule of administration of Mcl-1 inhibitors such as
UMI77 in combination with gemcitabine and radiation are the
critical next steps required in order to begin to advance Mcl-1
inhibitors to the clinic for the treatment of locally advanced
pancreatic cancer. Taken together, the findings of this study support
the continued development of selective inhibitors of Mcl-1 for
sensitizing pancreatic cancers to chemoradiation therapy.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2014.12.004.
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